Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • SKS Technologies Moves to Expand NSW Footprint With Delta Elcom Acquisition
    SKS Technologies Moves to Expand NSW Footprint With Delta Elcom Acquisition
    • News

  • Monash University Partners with HITIQ to Advance Concussion Science Using Smart Mouthguards
    Monash University Partners with HITIQ to Advance Concussion Science Using Smart Mouthguards
    • News

  • Harris Technology targets return to profitability amid surging Refurbished Tech sales and Apple expansion
    Harris Technology targets return to profitability amid surging Refurbished Tech sales and Apple expansion
    • News

  • Pivotal Metals Secures $5.4M to Fast-Track Quebec Drill Program
    Pivotal Metals Secures $5.4M to Fast-Track Quebec Drill Program
    • News

  • Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    • News

  • DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    • News

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

Healthia expands national presence with NSW acquisitions

  • In News
  • August 2, 2019
  • Alfred Chan
Healthia expands national presence with NSW acquisitions

Allied healthcare operator Healthia (ASX:HLA) has continued its clinic acquisition spree, this week announcing the addition of 4 hand therapy clinics in Sydney.

Since listing on the ASX in September 2018, Healthia has now acquired 26 new clinics across it’s podiatry and physio businesses with the latest round of clinics forecast to deliver annual earnings of $775,000, having been acquired for a total of $3.5m via a combination of cash and equity.

“The 4 speciality hand therapy clinics, which provide physiotherapy and occupational therapy for the hand and upper limb, complement our existing 9 Extend Hand Therapy clinics in Queensland,” said Tony Ganter, Healthia CEO of Physiotherapy.

“We are pleased that we are able to expand these speciality services across the group.”

These new acquisitions maintain Healthia’s momentum having last month acquired 6 podiatry and 3 physiotherapy clinics, further fueling their national expansion since listing.

Healthia’s acquisitions have been funded by a $37 million cash facility but one factor which has made partnership with Healthia attractive is the company’s unique Clinic Class Share model where partner-operators gain equity in the company’s national operations.

With cash consideration for the 26 clinic acquisitions since listing totalling $13.55 million, the company has flagged further national expansion plans for the Group which also operate DBS Medical Supplies and iOrthotics – one of Australia’s largest orthotics producers.

Canaccord has a price target on HLA of $1.45 (currently $1.08). However, price targets are speculative and investors should seek professional financial advice for further information if considering this stock for their portfolio.

 

*Owners of this website are shareholders in a company mentioned in this article and have been engaged by them to assist in investor communications

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  •  
  •  
  •  
  •  
  • hand therapy
  • healthia
  • HLA
  • Physitherapy
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.